Entrada Therapeutics (TRDA) Leases (2022 - 2025)
Historic Leases for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $62.1 million.
- Entrada Therapeutics' Leases fell 1579.3% to $62.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.1 million, marking a year-over-year decrease of 1579.3%. This contributed to the annual value of $71.1 million for FY2024, which is 1272.55% down from last year.
- Entrada Therapeutics' Leases amounted to $62.1 million in Q3 2025, which was down 1579.3% from $65.7 million recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' Leases registered a high of $88.3 million during Q2 2023, and its lowest value of $14.2 million during Q1 2023.
- Its 4-year average for Leases is $58.5 million, with a median of $68.4 million in 2025.
- In the last 5 years, Entrada Therapeutics' Leases tumbled by 5464.04% in 2023 and then surged by 45420.79% in 2024.
- Over the past 4 years, Entrada Therapeutics' Leases (Quarter) stood at $25.3 million in 2022, then soared by 221.59% to $81.5 million in 2023, then dropped by 12.73% to $71.1 million in 2024, then dropped by 12.65% to $62.1 million in 2025.
- Its last three reported values are $62.1 million in Q3 2025, $65.7 million for Q2 2025, and $68.4 million during Q1 2025.